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Abstract
Background—Depression is often undiagnosed and untreated. It is not clear if differences exist 
in the diagnosis and treatment of depression among pregnant and nonpregnant women. We sought 
to estimate the prevalence of undiagnosed depression, treatment by modality, and treatment 
barriers by pregnancy status among U.S. reproductive-aged women.
Methods—We identified 375 pregnant and 8,657 nonpregnant women 18–44 years of age who 
met criteria for past-year major depressive episode (MDE) from 2005–2009 nationally 
representative data. Chi-square statistics and adjusted prevalence ratios (aPR) were calculated.
Results—MDE in pregnant women (65.9%) went undiagnosed more often than in nonpregnant 
women (58.6%) (aPR 1.1, 95% confidence interval [CI] 1.0–1.3). Half of depressed pregnant 
(49.6%) and nonpregnant (53.7%) women received treatment (aPR 1.0, 95% CI 0.90–1.1), with 
prescription medication the most common form for both pregnant (39.6%) and nonpregnant 
(47.4%) women. Treatment barriers did not differ by pregnancy status and were cost (54.8%), 
opposition to treatment (41.7%), and stigma (26.3%).
Conclusions—Pregnant women with MDE were no more likely than nonpregnant women to be 
diagnosed with or treated for their depression.
Introduction
Depression is a leading cause of global disability and the second leading cause of global 
disease burden among people 15–44 years of age.1 Women are disproportionately affected, 
as they are almost twice as likely as men to report lifetime history of major depressive 
episode (MDE).2,3 Depression affects 8%–16% of U.S. reproductive-aged women2,4–6 and 
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is associated with concurrent psychiatric and substance use disorders7 and adverse 
reproductive outcomes, including decreased fertility8; poor pregnancy outcomes, such as 
preterm delivery or low birthweight (LBW) infant9,10; and impaired maternal functioning 
and bonding.11
Effective depression treatment for women includes counseling, behavioral therapy, exercise, 
and antidepressants.12 However, half or fewer of depressed women receive a diagnosis5 or 
treatment,4,7 and barriers to treatment are not well understood. Among depressed and treated 
women, prevalence by type of treatment is unknown and may differ by pregnancy status. 
Understanding the prevalence of pharmacotherapy among women is especially important 
because 49% of pregnancies are unintended13 and the effects of pre-natal antidepressant use 
on the fetus are not fully understood.10,14–18 Furthermore, whether depressed pregnant 
women are more likely to receive a diagnosis and treatment because of their frequent 
interactions with the healthcare system is unknown. Therefore, we estimate the prevalence 
and predictors of undiagnosed depression, treatment prevalence overall and by modality, and 
treatment barriers among a nationally representative population-based sample of U.S. 
reproductive-aged women.
Materials and Methods
Data source and participants
We used combined public use data from the 2005–2009 National Surveys on Drug Use and 
Health (NSDUH). The NSDUH, sponsored by the U.S. Substance Abuse and Mental Health 
Services Administration (SAMHSA), is a cross-sectional survey designed to estimate 
prevalence and correlates of substance use in U.S. household populations aged ≥12 years. 
The NSDUH samples the civilian, noninstitutionalized population using multistage area 
probability sampling to randomly sample households in 50 states and the District of 
Columbia.
Beginning in 2005, an adult depression module was administered in person via computer-
assisted instruments to all respondents aged ≥18 years. The overall weighted response rate 
for 2005–2009 was 67.6%.19–23 Detailed information about the sampling and survey 
methodology can be found elsewhere.19–23 As this study uses de-identified, publicly 
available data, approval by the Centers for Disease Control and Prevention (CDC), 
institutional review board was not required. Combined 2005–2009 data yielded 77,415 
female respondents aged 18–44 years. Of these, 76,772 women (99.2%) reported data on 
pregnancy status and MDE. A total of 9,032 reproductive-aged women reported having 
MDE in the year preceding the survey, referred to hereafter as past-year MDE.
Measures
Major depressive episode—MDE was assessed using nine questions about MDE 
symptoms, as defined by the Diagnostic and Statistical Manual of Mental Disorders (DSM-
IV).24 A respondent met DSM-IV criteria for past-year MDE if she reported experiencing 
≥5 symptoms nearly every day in the same 2-week period in the past 12 months, with at 
least 1 of the 5 symptoms being depressed mood or loss of interest or pleasure in daily 
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activities. Additionally, any self-reported functional impairment in home management, 
work, social life, or personal relationships due to depressive symptoms was examined. 
Women also self-reported whether a doctor or other medical professional had told them that 
they had depression in the past year, which was asked separately from MDE symptoms and 
is referred to hereafter as having a clinical diagnosis of depression.
Mental health treatment—Three NSDUH questions assessed past-year treatment. 
Respondents were asked: “During the past 12 months, did you take any prescription 
medication that was prescribed for you to treat a mental or emotional condition? During the 
past 12 months, did you receive any outpatient treatment or counseling for any problem you 
were having with your emotions, nerves, or mental health? During the past 12 months, have 
you stayed overnight or longer in a hospital or other facility to receive treatment or 
counseling for any problem you were having with your emotions, nerves, or mental health? 
Mental health treatment was defined as receiving prescription medication, counseling, or 
inpatient care in the past year.
Respondents who answered yes to the question: During the past 12 months, was there any 
time when you needed mental health treatment or counseling for yourself but didn’t get it? 
were classified as having unmet treatment needs. We classified barriers to mental health 
treatment as cost (could not afford cost, insurance did not cover at all, insurance did not pay 
enough), stigma (fear of neighbors’ negative opinion, fear of negative effects on job, 
confidentiality concerns, did not want others to find out), opposition to treatment (didn’t 
think treatment was needed at the time, could handle problems without treatment, didn’t 
think treatment would help, fear of being committed/medicated), time or transportation 
limitations (didn’t have time, no transportation, or inconvenient), and did not know where to 
go.
Pregnancy and sociodemographic characteristics—Women self-reported their 
pregnancy status. Demographic variables included self-reported age in years (18–25, 26–34, 
35–44), race/ethnicity (non-Hispanic white, African American, Hispanic, and other), 
education (less than high school, high school graduate, some college, college or more), 
employment (full-time, part-time, unemployed, and other, i.e., disabled, keeping house full-
time, in school/training, or retired), annual family income (< $20,000, $20,000–49,999, 
$50,000–74,999, ≥$75,000), marital status (married; widowed, divorced, or separated; never 
been married), and health insurance (public: Medicaid, Medicare, health care programs for 
uniformed service members, retirees, and families including TRICARE/CHAMPUS 
[Civilian Health and Medical Program of the Uniformed Services], CHAMPVA [Civilian 
Health and Medical Program of the Department of Veterans Affairs], Veterans Affairs, or 
other military health insurance, without private insurance; private: health insurance through 
employment; or uninsured). Whereas MDE and mental health treatment were assessed over 
the past year, women were asked to report current pregnancy and sociodemographic 
characteristics at the time of the interview.
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Chi-square tests were conducted to assess differential distribution of sociodemographic 
characteristics by pregnancy status. Separate multivariable general linear models with 
Poisson distribution were used to estimate the adjusted prevalence ratio (aPR) of not 
receiving a clinical diagnosis among women who met MDE criteria. Correlates of interest 
included pregnancy status, age, race, education, employment, income, marital status, and 
health insurance. In addition, we estimated the aPR of receiving any treatment in the past 
year and the aPR of receiving prescription medication in the past year, adjusted for diagnosis 
and the correlates listed previously. A sensitivity analysis was conducted on all three 
adjusted prevalence ratio models, restricting the sample to only women who experienced 
functional impairment with past-year MDE. The prevalence of self-reported treatment 
barriers was also examined by pregnancy status. All analyses were conducted using Stata 




Among all reproductive-aged women, the prevalence of past-year MDE was 10.9%, 
representing 1.2 million women per year in 2005–2009. Among women with past-year 
MDE, 99.6% self-reported some functional impairment in home management, work, social 
life, or personal relationships. The prevalence of past-year MDE among pregnant women 
was 7.7% compared with 11.1% among nonpregnant women (p < 0.001). Distributions of 
sociodemographic characteristics by pregnancy status among women with MDE are shown 
in Table 1. Pregnant women were more likely than nonpregnant women to be younger, have 
other employment, be married, and have public insurance (p < 0.01). Fewer pregnant women 
(14.6%) with past-year MDE were uninsured compared to nonpregnant women with past-
year MDE (21.6%).
Clinical diagnosis of depression
Among women who met DSM-IV criteria for MDE, 58.8% did not receive a clinical 
diagnosis in the past year (Table 2). Pregnant women (65.9%) had a higher prevalence of 
undiagnosed depression compared to nonpregnant women, although this did not reach 
statistical significance (58.6%) (p = 0.06, aPR 1.1, 95% confidence interval, [CI] 1.0–1.3). 
Women with a high prevalence of undiagnosed depression were younger (65.8%), African 
American (73.1%), Hispanic (68.0%), of other racial and ethnic groups (67.6%), and 
uninsured (65.8%). In adjusted analyses, these same groups of women had statistically 
significantly higher PRs for having undiagnosed depression, although associations were 
attenuated, and aPRs ranged from 1.1. to 1.4. Restriction of the sample to women with past-
year MDE symptoms and functional impairment did not change the results (data not shown).
Mental health treatment
An estimated 49.6% of pregnant women and 53.7% of nonpregnant women with past-year 
MDE received mental health treatment in the past year (prescription medication, counseling, 
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or inpatient care) but the difference between groups was not statistically significant (p = 
0.21) (Fig. 1). Among women with past-year MDE, prescription medication was most 
commonly reported by pregnant (39.6%) and non-pregnant women (47.4%), followed by 
counseling (36.3% of pregnant and 35.5% of nonpregnant women), and the least common 
treatment modality was inpatient care (7.2% of pregnant and 4.7% of nonpregnant women). 
Of the three treatment modalities, only the prevalence of prescription medication differed 
between pregnant and nonpregnant women (p = 0.04). Among all women with MDE 
receiving treatment, 55.4% received both counseling and prescription medication (95% CI 
53.1–57.7), with no differences by pregnancy status (data not shown).
Women with past-year MDE were more than twice as likely to receive treatment if they had 
a clinical diagnosis (68.0%) compared with undiagnosed women (32.0%, p < 0.001) (data 
not shown). Among women with past-year MDE, pregnant women were just as likely to 
receive any treatment (aPR 1.0, 95% CI 0.9–1.1) and, specifically, prescription medication 
(aPR 0.93, 95% CI 0.8–1.1) as nonpregnant women, after adjusting for clinical diagnosis 
and sociodemographic characteristics (data not shown). Restriction of the sample to women 
with past-year MDE symptoms and functional impairment did not change the results (data 
not shown).
Unmet treatment need and barriers to receiving treatment
Overall, 38.9% (95% CI 37.1–40.6) of women with past-year MDE reported unmet 
treatment needs in the past year (data not shown). Among these women, common treatment 
barriers were cost (54.8%, 95% CI 51.7–57.9), opposition to treatment (41.7%, 95% CI 
39.3–44.1), stigma concerns (26.3%, 95% CI 24.1–28.6), time or transportation limitations 
(18.1%, 95% CI 16.0–20.4), and not knowing where to go for treatment (16.7%, 95% CI 
14.9–18.6) (data not shown). Unmet treatment needs and treatment barriers did not differ by 
pregnancy status. Unmet treatment need was higher among women with a clinical diagnosis 
(48.6%) than among undiagnosed women (32.2%) (p < 0.001). Treatment barriers were 
similar between those with and without a diagnosis, although more women with a clinical 
diagnosis (18.6%) knew where to go for treatment compared with undiagnosed women 
(14.9%) (p = 0.02).
Discussion
We found that > 1 in 10 reproductive-aged women met criteria for MDE in the past year, 
representing approximately 1.2 million U.S. women. Additionally, about 60% who met 
criteria for past-year MDE did not receive a diagnosis of depression, and almost half did not 
receive any mental health treatment. Pregnant women were no more likely to receive a 
diagnosis or treatment than were nonpregnant women. Prescription medication was the most 
common treatment for past-year MDE among both pregnant and nonpregnant women. The 
top three barriers to mental health treatment for pregnant and nonpregnant women were cost, 
opposition to treatment, and stigma.
Prevalence estimates of past-year MDE in this study are consistent with other national 
studies for reproductive-aged women.4,5 We found that the prevalence of MDE among 
pregnant women was lower than among nonpregnant women, consistent with another 
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nationally representative study that found that the prevalence of major depressive disorder 
was 5.6% among pregnant women compared to 8.1% among non-pregnant reproductive-
aged women.4 A diagnosis of depression is often the first step toward receiving treatment. In 
this study, women with a diagnosis were more than twice as likely to receive treatment. 
However, about 60% of reproductive-aged women with past-year MDE in our study did not 
receive a clinical diagnosis of depression in the past year. This is a concern, as 
approximately 73% of reproductive-aged women see a clinician for reproductive health 
concerns at least annually25 and, thus, have an opportunity to discuss their mental health or 
be screened for depression by a medical professional.
We also found that past-year depression in pregnant women more often went undiagnosed 
compared with non-pregnant women, even though pregnant women tend to interact with the 
healthcare system more than nonpregnant women, averaging once every month during a 
pregnancy.26 We had data only on past-year depressive episodes, and some women were not 
pregnant when they experienced the reported depressive symptoms. However, the lower 
prevalence of diagnosis among pregnant women suggests that prenatal care providers may 
miss opportunities to identify and connect pregnant women with MDE to mental health 
services or that pregnant women are receiving screening and referrals but not seeking 
specialized care for diagnosis and treatment. Other studies have found that psychiatric 
disorders often go unrecognized and undiagnosed by obstetricians27 and gynecologists27–29 
and that depression screening rates among their patients are low, with one study finding that 
only 9%–12% of obstetricians and gynecologists routinely ask or screen for depressive 
symptoms.29 The rates of depression diagnosis may be low in part because the U.S. 
Preventive Services Task Force (USPSTF) recommends screening adults for depression only 
when staff-assisted depression care supports are in place to ensure accurate diagnosis, 
effective treatment, and follow-up.30 Clinicians who are unprepared to treat depression and 
have no place to refer uninsured women appropriately may not screen. Although the 
American College of Obstetricians and Gynecologists (ACOG) states that “at this time, there 
is insufficient evidence to support a firm recommendation for universal antepartum or 
postpartum screening,” it also states that “screening for depression has the potential to 
benefit a woman and her family and should be strongly considered.”31 Continued support 
for depression screening by ACOG and continued efforts to promote greater awareness of 
the issue among their members may lead to increased screening rates among providers. 
Additionally, increasing the availability of and access to affordable treatment may improve 
depression diagnosis and treatment.
Approximately half of pregnant and nonpregnant women with past-year MDE did not 
receive treatment. This is consistent with national estimates of depression treatment among 
the general adult population32,33 and reproductive-aged women with serious psychologic 
distress.5 However, our estimates are lower than rates reported among reproductive-aged 
women with any mood disorder.4 A national study using 2001–2002 National 
Epidemiologic Survey on Alcohol and Related Conditions (NESARC) data, conducted by 
the National Institute on Alcohol Abuse and Alcoholism, found that the prevalence of not 
receiving treatment for mood disorder was significantly higher among past-year pregnant 
(86%) and postpartum (85%) women than among nonpregnant women (74%).4 These 
discrepancies may be due to differences in definitions. The NESARC study estimated 
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treatment for any mood disorder, which included major depressive disorder, dysthymia, and 
bipolar disorder,4 whereas our study estimated any treatment for emotions, nerves, or mental 
health among women with MDE. Together, these national studies indicate that mental health 
treatment is highly underused among depressed, reproductive-aged women.
The low rate of depression diagnosis may explain treatment underuse, as our study also 
found that almost 90% of women who received a diagnosis of depression also received some 
form of treatment. Among diagnosed women, however, treatment barriers still exist, with > 
48% reporting an unmet treatment need. Younger women, women of racial/ethnic minority 
groups, and uninsured women were the least likely to receive diagnoses. Disparities among 
these groups are also reflected in the top three barriers to mental health treatment: cost, 
opposition to treatment, and stigma. Certain racial/ethnic minority groups and uninsured 
people consistently demonstrate unmet mental health treatment need in national studies of 
reproductive-aged women5 and the general adult population.32–35 Several studies have 
demonstrated that African Americans and Hispanics perceive greater stigma36,37 and have 
more negative beliefs about the usefulness and effectiveness of anti-depressant medication 
and counseling compared with non-Hispanic whites.38
We found that reproductive-aged women with past-year MDE most often used prescription 
medication, followed by counseling and inpatient care, and that type of treatment did not 
vary by pregnancy status after adjustment for covariates. Our prevalence estimates of 
treatment modality are similar to those reported for the general U.S. adult population.39 
Although prevalence of inpatient care was low, it equates to receipt of inpatient care by over 
52,000 reproductive-aged women with severe mental health conditions each year. Our study 
found that 2 of 5 reproductive-aged women with MDE use prescription medication for 
mental health treatment; this is important because half of pregnancies are unintended,25 and 
the effects of antidepressants on the fetus and breastfed infant are not fully understood. Past 
research suggests possible associations between prenatal antidepressant use and miscarriage, 
LBW infants, and infant persistent pulmonary hypertension10,14–16; associations between 
depression and preterm birth and LBW infants have also been observed.9,10
Study limitations
There were several study limitations. First, data were available only on pregnancy status at 
the time of the interview and not in the past year. Thus, past-year MDE and past-year 
diagnosis may not have occurred during the pregnancy; on average, pregnant women were 
in their second trimester. Second, we could not identify postpartum women using publicly 
available data; however, only 6.9% (95% CI 6.7–7.1) of nonpregnant women aged 18–44 
years reported having a child < 1 year of age in the household (personal communication with 
NSDUH staff regarding data in 2002–2009 non-public use files). Therefore, including 
postpartum women in the nonpregnant group likely had little effect on prevalence estimates. 
Third, depressive symptoms were not clinically validated, and mental health diagnosis and 
treatment were self-reported. Women may be reluctant to disclose depressive symptoms, 
diagnosis, or treatment, although use of computer-assisted interviews may lessen this bias. 
Fourth, mental health treatment was not specific to MDE but was rather for emotions, 
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nerves, or mental health; thus, we may have overestimated treatment for depression, as 
treatment could have been for other psychiatric disorders, such as anxiety.
This study is the first, to our knowledge, to report treatment prevalence by modality and 
treatment barriers among a nationally representative sample of pregnant and non-pregnant 
reproductive-aged women. The large dataset and multiple years of data enabled us to stratify 
estimates by pregnancy status and increase our power to detect associations. Computer-
assisted data collection also lessened social desirability bias.
Findings from this study lead to a few public health implications. First, as reproductive-aged 
women periodically see medical providers for contraception and more often for pregnancy 
or other reproductive health concerns, reproductive health visits may be opportunities to 
assess depressive symptoms and refer women to care if needed. Second, expanded insurance 
coverage for mental health treatment is needed because depression often goes untreated, 
especially among the uninsured, and because cost was the most common treatment barrier. 
Finally, given the high prescription medication use among women with past-year MDE, a 
greater understanding is needed about the antidepressant effects on fetuses and breastfed 
infants so that women, with the help of their providers, can make informed decisions about 
mental health treatment during pregnancy and while breastfeeding.
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Table 1
Characteristics of Women with Past-Year Major Depressive Episode, by Pregnancy Status (n = 9,032), 
National Survey on Drug Use and Health, 2005–2009
Characteristic Pregnanta % (95% CI) n = 375 Nonpregnanta % (95% CI) (n = 8,657) p value
Age, years
 18–25 48.6 (41.1–56.2) 31.0 (29.6–32.5) < 0.001
 26–34 39.0 (30.9–47.7) 30.3 (28.7–32.0)
 35–44 12.4 (7.1–20.7) 38.7 (36.7–40.6)
Race/ethnicity
 Non-Hispanic white 74.0 (65.8–80.8) 71.2 (70.0–72.5) 0.35
 African American 10.0 (6.5–15.0) 11.6 (10.5–12.7)
 Hispanic 13.1 (8.9–18.9) 11.9 (10.7–13.1)
 Other 2.9 (1.6–5.4) 5.4 (4.7–6.2)
Education
 Less than high school 18.7 (14.5–23.8) 14.7 (13.6–15.9) 0.35
 High school 30.7 (24.5–37.8) 29.1 (27.6–30.6)
 Some college 29.5 (23.4–36.3) 33.6 (32.2–35.0)
 College 21.1 (14.7–29.3) 22.7 (21.2–24.2)
Employment
 Full-time 37.0 (29.6–45.1) 47.6 (46.0–49.2) < 0.001
 Part-time 16.8 (12.6–22.0) 20.0 (18.9–21.1)
 Other 40.0 (32.4–48.1) 25.0 (23.6–26.5)
 Unemployed 6.3 (3.8–10.1) 7.4 (6.7–8.3)
Income
 ≥$75,000 23.0 (16.5–31.0) 20.3 (18.5–22.1) 0.62
 $50,000–$74,999 15.0 (9.9–22.2) 15.9 (14.7–17.2)
 $20,000–$49,999 32.6 (26.2–39.7) 37.0 (35.1–38.9)
 < $20,000 29.5 (23.2–36.6) 26.9 (25.4–28.5)
Marital status
 Married 49.0 (40.9–57.1) 36.7 (34.9–38.6) 0.003
 Divorced, separated, or widowed 10.9 (7.2–16.1) 19.1 (17.7–20.7)
 Never married 40.2 (33.1–47.6) 44.2 (42.4–45.9)
Health insurance
 Uninsured 14.6 (9.4–22.0) 21.6 (20.4–22.8) < 0.001
 Public 40.8 (33.3–48.8) 21.9 (20.4–23.5)
 Private 44.6 (36.3–53.1) 56.5 (54.8–58.1)
a
Total percentages may not sum to 100.0% because of rounding. CI, confidence interval.
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Table 2
Correlates of Not Receiving Clinical Diagnosis of Depression in Past Year Among Women Who Met DSM-
IV Criteria for Past-Year Major Depressive Episode, National Survey on Drug Use and Health, 2005–2009
Diagnosed % (95% CI) No diagnosis % (95% CI) Chi-square p-value No diagnosis aPR (95% CI)
Total 41.2 (39.3–43.0) 58.8 (57.0–60.7)
Pregnancy status
 Pregnant 34.1 (27.1–41.9) 65.9 (58.1–72.9) 0.06 1.1 (1.0–1.3)
 Nonpregnant 41.4 (39.5–43.3) 58.6 (56.7–60.5) 1.0
Age, years
 18–25 34.2 (32.7–35.7) 65.8 (64.3–67.3) < 0.001 1.2 (1.1–1.2)
 26–34 42.1 (38.4–46.0) 57.9 (54.0–61.6) 1.0 (0.9–1.1)
 35–44 46.2 (43.0–49.4) 53.8 (50.6–57.0) 1.0
Race/ethnicity
 Non-Hispanic white 45.6 (43.5–47.8) 54.4 (52.2–56.5) < 0.001 1.0
 African American 26.9 (22.9–31.5) 73.1 (68.5–77.2) 1.4 (1.3–1.5)
 Hispanic 32.0 (27.7–36.6) 68.0 (63.4–72.3) 1.2 (1.2–1.3)
 Other 32.4 (26.0–39.6) 67.6 (60.4–74.0) 1.2 (1.1–1.4)
Education
 Less than high school 38.8 (34.5–43.2) 61.2 (56.8–65.5) 0.48 1.0 (0.9–1.2)
 High school 42.3 (39.5–45.3) 57.7 (54.8–60.6) 1.0 (0.9–1.0)
 Some college 41.8 (39.4–44.3) 58.2 (55.7–60.7) 1.0 (0.9–1.0)
 College 40.2 (36.3–44.3) 59.8 (55.7–63.8) 1.0
Employment
 Full-time 38.8 (36.1–41.7) 61.2 (58.3–64.0) 0.002 1.0 (0.9–1.1)
 Part-time 40.1 (36.8–43.5) 59.9 (56.5–63.2) 1.0 (0.9–1.1)
 Other 47.1 (43.2–51.1) 52.9 (48.9–56.8) 1.0 (0.8–1.0)
 Unemployed 38.3 (32.6–44.5) 61.7 (55.5–67.4) 1.0
Income
 ≥$75,000 38.8 (34.9–42.9) 61.2 (57.2–65.1) 0.47 1.1 (1.0–1.2)
 $50,000–$74,999 42.9 (38.6–47.4) 57.1 (52.6–61.4) 1.0 (0.9–1.1)
 $20,000–$49,999 41.7 (38.8–44.7) 58.3 (55.3–61.2) 1.0 (0.9–1.1)
 < $20,000 41.1 (38.2–44.1) 58.9 (56.0–61.8) 1.0
Marital status
 Married 44.7 (41.3–48.1) 55.3 (51.9–58.7) < 0.001 1.0 (0.9–1.1)
 Divorced, separated, or 
widowed
45.4 (40.9–50.0) 54.6 (50.0–59.1) 1.0 (0.9–1.1)
 Never married 36.4 (34.2–38.6) 63.6 (61.4–65.8) 1.0
Health insurance
 Uninsured 34.2 (31.3–37.3) 65.8 (62.7–68.7) < 0.001 1.1 (1.0–1.2)
 Public 48.4 (45.2–51.6) 51.6 (48.4–54.8) 0.9 (0.8–0.9)
 Private 40.9 (38.4–43.4) 59.1 (56.6–61.6) 1.0
aPR, adjusted prevalence ratio compared to diagnosis and adjusted for sociodemographic characteristics listed.
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